Emergent BioSolutions stopped production in April. The Food and Drug Administration is close to authorizing Emergent BioSolutions’ Baltimore facility to produce Covid-19 vaccine, the Wall Street ...
Emergent BioSolutions announced Thursday that the US Food and Drug Administration will allow it to resume the manufacturing of the drug substance that goes into Johnson & Johnson’s Covid-19 vaccine.
The report sheds new light on executives’ worries about deficiencies in the company’s quality control systems at its troubled Baltimore plant; no contaminated doses were ever released to the public.
An Operation Warp Speed report last June flagged staffing and quality control concerns at Emergent BioSolutions’ factory in Baltimore. The troubled plant recently had to throw out up to 15 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results